News

Six partners seek kinase drugs
Enlarge image

ResearchEU

Six partners seek kinase drugs

11.04.2013 - Fuelled by €1.1m of EU money, six European partners from industry and academia plan to find kinase-targeting drugs in a venture called TAKTIC.

A focussed group of three SMEs and three academic partners form the Translational Kinase Tumour Inhibitor Discovery Consortium (TAKTIC). Members announced on 10 April the creation of the consortium which is financed to the tune of €1.1m by the EU’s 7th Framework Programme “Research for the Benefit of SMEs”. The industry partners comprise SARomics Biostructures from Lund (Sweden), Prestwick Chemical from Illkirch (France) and ProQinase GmbH from Freiburg (Germany). The collaborating academic scientists work at the University of Turin (Italy) the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science and the TechMedIll platform of the University of Strasbourg (France).

Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium offers its members extensive expertise in medicinal chemistry, kinase biochemistry as well as state-of-the-art high-throughput platforms for protein expression and crystallisation. The merging of the highly complementary capabilities of the six partners within TAKTIC enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases, the partners said in a joint press release.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2013-02/six-partners-seek-kinase-drugs.html

DiabetesFrance

01.09.2015 Sanofi is partnering up with Google’s life sciences team with an ambitious goal: to change the face of diabetes management.

M&ASwitzerlandFrance

31.08.2015 In order to boost its active cosmetic ingredients business, the Swiss flavour and fragrance giant Givaudan has acquired Volketswil-based Induchem Holding and all its subsidiaries.

BioeconomyEU

26.08.2015 In its second call for proposals, the Bio-Based Industries Joint Undertaking has earmarked €106m for the research and development of useful bio-based products.

OncologyNorway

25.08.2015 Oslo Cancer Cluster is inaugurating its NOK1bn (€107m) Innovation Park. None other than Norwegian prime minister Erna Solberg officially opened the doors to the research park on August 24th.

LicensingUKSwitzerland

21.08.2015 Novartis Pharma AG has secured all remaining rights to antibody hopeful ofatumumab. Seller GlaxoSmithKline is set to receive up to US$1bn (€919m) for the treatment for MS and other autoimmune indications.

LicensingDenmark

18.08.2015 Danish Novo Nordisk is climbing on the antibody therapeutics bandwagon in a US$500m licensing agreement with antibody-specialist Genmab.

M&ASwitzerland

13.08.2015 Roche is stepping up its commitment in the fight against drug resistant “superbugs” with its takeover of US diagnostics play Geneweave, for up to US$425m.

M&AUK

11.08.2015 Biotech bug controllers Oxitec has been bought by US biotech Intrexon Corporation for $160m (€145m). The Oxford University spin-out specialises in environmentally friendly technology to control pests such as mosquitoes, which cause dengue fever and other diseases.

Research and DevelopmentFranceGermany

07.08.2015 In a deal worth more than €300m, Sanofi has partnered up with German drug discovery and development company Evotec in order to develop beta cell-modulating diabetes therapies.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • 4SC (D)3.54 EUR10.62%
  • DEINOVE (F)7.10 EUR7.25%
  • NANOBIOTIX (F)18.43 EUR5.62%

FLOP

  • BIOTIE THERAPEUTICS (FI)0.20 EUR-9.09%
  • OREXO (S)45.30 SEK-8.67%
  • TIGENIX (B)1.12 EUR-7.44%

TOP

  • KARO BIO (S)40.60 SEK2486.0%
  • BIOTECH PHARMACON (N)17.40 NOK87.1%
  • TRANSGENE (F)4.86 EUR75.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-50.0%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-42.9%
  • BIONOR PHARMA (N)1.17 NOK-42.6%

TOP

  • KARO BIO (S)40.60 SEK4513.6%
  • ADOCIA (F)85.64 EUR388.3%
  • VERONA PHARMA (UK)4.95 GBP312.5%

FLOP

  • CHRONTECH PHARMA (S)0.01 SEK-87.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)12.85 SEK-79.3%
  • BIOTEST (D)20.00 EUR-76.9%

No liability assumed, Date: 03.09.2015